Patents by Inventor Eric A. Murphy

Eric A. Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130266636
    Abstract: In alternative embodiments, the invention provides methods for regulating or modulating RAF kinases. In alternative embodiments, the invention provides methods for ameliorating, preventing and/or treating diseases, infections and/or conditions having unwanted, pathological or aberrant cell proliferation, or that are responsive to inhibition or arrest of cell growth, by administration of an allosteric RAF inhibitor and/or any agent which prevents localization of RAF to mitotic spindles or mid-bodies.
    Type: Application
    Filed: August 12, 2011
    Publication date: October 10, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Eric Murphy, Ainhoa Mielgo
  • Publication number: 20130123284
    Abstract: Provided herein are compounds useful for kinase inhibition.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 16, 2013
    Applicant: AMITECH THERAPEUTIC SOLUTIONS INC
    Inventors: Lee Daniel Arnold, Eric A. Murphy
  • Publication number: 20130117887
    Abstract: This disclosure provides a novel herbicide resistant plant, a method to transform Camelina sativa for herbicide resistance and a method for an improved in vitro regeneration of transformed plants.
    Type: Application
    Filed: October 5, 2011
    Publication date: May 9, 2013
    Inventors: Seppo Paavo Kaijalainen, Kimmo Koivu, Viktor Kuvshinov, Eric Murphy
  • Patent number: 8222404
    Abstract: The invention is directed to a [7-methanesulfonylamino-methyl)-1,1-dioxo-1,4-dihydro-1?6-thieno[2,3-e][1,2,4]thiadiazin-3-yl]-acetic acid compound and to methods of making the same.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: July 17, 2012
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Peter Dragovich, Douglas Eric Murphy
  • Patent number: 8148602
    Abstract: The invention relates to isolated diacylglycerol acyltransferases and polynucleotide sequences encoding the DGAT enzymes; polynucleotide constructs, vectors and host cells incorporating the polynucleotide sequences; and methods of producing and using same. Also provided are transformed cells and transgenic plants, especially Camelina sativa plant, with enhanced oil accumulation and quality.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: April 3, 2012
    Inventors: Randall Weselake, Rodrigo Siloto, Qin Liu, André Laroche, Eric Murphy, Kimmo Koivu
  • Publication number: 20120021036
    Abstract: The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.
    Type: Application
    Filed: January 14, 2010
    Publication date: January 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Bharat Majeti, Eric Murphy, Wolfgang Wrasidlo, David Cheresh
  • Patent number: 8097613
    Abstract: The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds of formula I wherein A is B is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: January 17, 2012
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Frank Ruebsam, Peter Dragovich, Stephen E. Webber, Douglas Eric Murphy, Chinh Viet Tran
  • Patent number: 7935699
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: May 3, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Ramakanth Sarabu, Chinh Viet Tran, Dionisios Vourloumis
  • Patent number: 7902248
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I): that are useful for the treatment of metabolic diseases and disorders.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: March 8, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Chinh Viet Tran, Dionisios Vourloumis
  • Patent number: 7842838
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: November 30, 2010
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Frank Ruebsam, Martin Tran, Peter Dragovich, Liansheng Li, Douglas Eric Murphy, David Kucera, Zhongxiang Sun, Chinh Viet Tran
  • Publication number: 20100209488
    Abstract: The invention provides compositions, e.g., small molecules, that disrupt the activity of protein kinases, including constitutively activated protein kinases, such as kinases constitutively activated through mutations, and kinases in their native inactivated state, and methods for making and using them. In one aspect, compositions of the invention bind a protein kinase in its inactive conformation involving the conserved asparagine-phenylalanine-glycine residue motif, or “Asp-Phe-Gly” or “DFG” motif, of the activation loop in the allosteric binding site. The small molecule protein kinase inhibitors of the invention comprise or are derivatives or analogs of oxadiazoles, thiadiazoles, oxazoles, thiazoles, arylamides, quinolones, pyrazoles, pyrazolones, imides, pyrolles, imidazoles and/or triazoles.
    Type: Application
    Filed: July 15, 2008
    Publication date: August 19, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Wolfgang Wrasidlo, Eric Murphy, David Cheresh
  • Publication number: 20090249516
    Abstract: The invention relates to isolated diacylglycerol acyltransferases and polynucleotide sequences encoding the DGAT enzymes; polynucleotide constructs, vectors and host cells incorporating the polynucleotide sequences; and methods of producing and using same. Also provided are transformed cells and transgenic plants, especially Camelina sativa plant, with enhanced oil accumulation and quality.
    Type: Application
    Filed: March 9, 2009
    Publication date: October 1, 2009
    Applicants: University of Alberta, Agru-Food
    Inventors: Randall Weselake, Rodrigo Siloto, Qin Liu, Andre Laroche, Eric Murphy, Kimmo Koivu
  • Patent number: 7582754
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: September 1, 2009
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Frank Ruebsam, Martin Tran, Peter Dragovich, Liansheng Li, Douglas Eric Murphy, David Kucera, Zhongxiang Sun, Chinh Viet Tran
  • Publication number: 20080146625
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I): that are useful for the treatment of metabolic diseases and disorders.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 19, 2008
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Chinh Viet Tran, Dionisios Vourloumis
  • Publication number: 20080021032
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
    Type: Application
    Filed: July 19, 2007
    Publication date: January 24, 2008
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Ramakanth Sarabu, Chinh Viet Tran, Dionisios Vourloumis
  • Patent number: 7053206
    Abstract: A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: May 30, 2006
    Assignee: Affymetrix, Inc.
    Inventors: Hajime Matsuzaki, Eric Murphy
  • Publication number: 20050112657
    Abstract: A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 26, 2005
    Applicant: AFFYMETRIX, INC
    Inventors: Haiime Matsuzaki, Eric Murphy
  • Publication number: 20040126806
    Abstract: A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.
    Type: Application
    Filed: December 23, 2003
    Publication date: July 1, 2004
    Applicant: AFFYMETRIX, INC.
    Inventors: Hajime Matsuzaki, Eric A. Murphy
  • Patent number: 6673579
    Abstract: A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: January 6, 2004
    Assignee: Affymetrix, Inc.
    Inventors: Hajime Matsuzaki, Eric Murphy
  • Publication number: 20020058281
    Abstract: A method is described for predetermining ratios of primer pairs present in a single reaction vessel so as to achieve approximately equimolar yield of products. The ratios are determined as a function of the length of the amplicon and the length of other amplicons being simultaneously tested. The primers may desirably be for p53 gene sequences.
    Type: Application
    Filed: November 21, 2001
    Publication date: May 16, 2002
    Applicant: AFFYMETRIX, INC.
    Inventors: Hajime Matsuzaki, Eric A. Murphy